SCHEDULE: Glazer Capital Reduces Stake in scPharmaceuticals Below 5%

Glazer Capital and Paul J. Glazer have reported a reduction in their beneficial ownership of scPharmaceuticals Inc. common stock to 4.64%, falling below the 5% threshold.

Summary

• Glazer Capital, LLC and Paul J. Glazer, collectively referred to as the Reporting Persons, have filed a Schedule 13G indicating a change in their beneficial ownership of scPharmaceuticals Inc. common stock.
• As of the event date, the Reporting Persons beneficially owned 2,474,820 shares of scPharmaceuticals Inc. common stock.
• This amount represents 4.64% of the outstanding common stock of scPharmaceuticals Inc.
• The Reporting Persons have shared voting power and shared dispositive power over all 2,474,820 shares.
• The filing explicitly states that as of the date of the filing, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake below the 5% threshold, which can be interpreted as a decrease in confidence or a strategic divestment.

Negatives

• A significant institutional investor, Glazer Capital, has reduced its stake in scPharmaceuticals Inc. to below the 5% beneficial ownership threshold, which can be perceived as a decrease in institutional conviction or support for the company.

Future Outlook

No forward-looking statements or guidance were provided by the issuer or reporting persons in this filing.

Industry Context

This filing reflects a change in institutional ownership for scPharmaceuticals Inc., a common occurrence in the biotechnology or pharmaceutical sector where investor sentiment and portfolio rebalancing frequently lead to adjustments in holdings. Such changes are closely watched by the market as indicators of investor confidence.

Stakeholder Impact

• Shareholders may perceive the reduction in institutional ownership as a negative signal, potentially impacting investor confidence and the company's stock price.
• The change in ownership does not directly impact employees, customers, suppliers, or creditors, as it is a passive investment disclosure.

Key Dates

Keywords

scPharmaceuticals Inc., Glazer Capital, Paul J. Glazer, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Stake Reduction